A phase I trial of CC-486, lenalidomide, obinutuzumab in relapsed/refractory indolent non-Hodgkin lymphoma. Othman T, Marquez-Arreguin G, Esteghamat N, Tuscano J, et al. Leuk Lymphoma 2024 Dec 28:1-4. doi: 10.1080/10428194.2024.2443552.

Read + Share

Amedeo Smart

Independent Medical Education

Othman T, Marquez-Arreguin G, Esteghamat N, Tuscano J, et al. A phase I trial of CC-486, lenalidomide, obinutuzumab in relapsed/refractory indolent non-Hodgkin lymphoma. Leuk Lymphoma 2024 Dec 28:1-4. doi: 10.1080/10428194.2024.2443552.
PMID: 39731545